Wellgistics Health

WGRX

Market cap $57.9M

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes.

TAMPA, FLORIDA / ACCESS Newswire / December 4, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription drug routing into blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey, today announced that it set a record date of December 19, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin. Shareholders will receive one (1) Dream Bowl 2026 Meme Coin from every one (1) share of Wellgistics Health owned upon the record date.

Company plans to distribute Dream Bowl 2026 Meme Coin to shareholders as of a to-be-determined December 2025 date with distribution expected in January 2026 TAMPA, FLORIDA / ACCESS Newswire / November 26, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence prescription routing for the physical dispensing of prescription drugs with PharmacyChain™ blockchain-enabled smart contracts to optimize the tracking, dispending and insurance coverage of prescription pharmaceutical drugs from manufacturer to dispensing from pharmacy to patient, today announced that it is sponsoring Dream Bowl 2026 and participation in the DataVault AI (NASDAQ:DVLT) Shareholder Distribution Plan. The Company expects to set (1) a record date and (2) a distribution date for the Dream 2026 Meme Coin to its shareholders; both are expected to occur in December 2025.

TAMPA, FL / ACCESS Newswire / November 20, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization of healthcare technology infrastructure into the individual patient fulfillment of prescription drug through pharmacies ‘From Manufacturer To Patient', today reported financial results for the period ended September 30, 2025 on Form 10-Q on November 19, 2025 [1] and provided a business update from the CEO. "The last 6 weeks have really allowed me to understand the different stages of development of the various parts of the business after I was reappointed as President and given the title of Interim-CEO on October 6, 2025," said Prashant Patel, RPh, President and Interim-CEO of Wellgistics Health.

TAMPA, FL / ACCESS Newswire / November 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of the physical and technology healthcare infrastructures for prescription drug distribution from manufacturer to patient through licensed pharmacies, today announced that it will report third quarter 2025 provide a business update and report financial results for the period ended September 30, 2025 on the morning of Thursday, November 20, 2025. About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is pharmacy physical and technology enabling health IT company that specializes in optimizing the delivery medications from manufacturers to patients.

Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network (‘Pharmacy Network') and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030 Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid® to Galectovid 1 & 3 inhibitor Medical Food Galectovid® distribution agreement to Pharmacy Network & physicians TAMPA, FLORIDA / ACCESS Newswire / November 14, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has expanded its agreement with Tollo Health to offer the first GLP-1 companion muscle loss medical food to its 6,500+ independent pharmacy network (‘Pharmacy Network') and physicians. The product is a branded version of a proprietary formulation that has been widely studied in metabolic dysfunction, with patients presenting diabetes type 2, heart failure, and COPD.

Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market TAMPA, FL / ACCESS Newswire / November 12, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has launched EinsteinRx™, the premier prescription management solution to integrate physical and technology infrastructure for the prescription drug industry. EinsteinRx allows for the fully customizable, seamless flow of information from the physician to the pharmacy, integrating drug manufacturing data, insurance information, patient data, nutritional recommendations and prescription fulfillment data in order to deliver an optimal solution for all key stakeholders.

KareRx to add plug & play telemedicine pharmacy-support vertical and key manufacturer relationships to Wellgistics' offering Telemedicine remote dispensing market expected to grow from $6.7 billion in 2025 to $13.57 billion by 2032 according to Fortune Business Insights Tampa, Florida--(Newsfile Corp. - November 4, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a non-binding letter of intent to acquire Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal and specialty pharmaceutical 'lite' branded products from Kare Pharmtech, LLC, a company owned by Dr. Kiran Patel, MD. The all-stock transaction is expected to close by January 31, 2026.

Powered by DataVault AI's High-Performance Computing & Information Exchange, Data Monetization for Traditional and Compound Pharmacies is Set to Become a Reality in the $639 Billion Prescription Drug Market, with Beta Testing Expected in First Half of 2026 Tampa, Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (NASDAQ: DVLT) ("DataVault"), a pioneering technology company leading the way in AI data experience, valuation, and monetization, to begin the development of manufacturer-to-patient blockchain-enabled smart contracts ("PharmacyChain™") being designed to optimize Wellgistics' proprietary technology and physical infrastructure for the prescription drug industry. The companies expect to finalize the related profit-sharing license agreement in the fourth quarter of 2025, once all various potential revenue streams stemming from the partnership are identified and valued.

Wellgistics Health Inc (NASDAQ: WGRX) more than tripled this morning after announcing a non-binding letter of intent with Datavault AI Inc. (NASDAQ: DVLT). The initiative dubbed “PharmacyChain” will integrate blockchain-enabled smart contracts into its prescription drug tracking system.